09/06/2026
Case Study: Successful Myopia Control with Combination Therapy (Defocus Spectacle Lenses and Low-Dose Atropine 0.01%)
A 15-year-old Indian girl attended Family Eyecare Optometry Centre for myopia management. In May 2020, her refraction was -5.50 D in the right eye and -4.50 D in the left eye. Despite wearing Executive Bifocal spectacles, her myopia progressed rapidly over the following 18 months to -7.75 D (right eye) and -6.75 D (left eye).
Due to the significant progression, combination treatment with Defocus Spectacle Lenses and Myopine 0.01% eye drops was initiated in November 2021.
At follow-up visits in March 2022, November 2023, and January 2026, her myopia remained largely stable. The final refraction in January 2026 was:
Right Eye: -7.75/-0.75 × 140 (6/6)
Left Eye: -7.00/-0.50 × 10 (6/6)
Axial length measurements also showed minimal change during the treatment period. The right eye increased from 26.14 mm to 26.31 mm, while the left eye remained stable at approximately 26.03 mm.
Over more than four years of treatment, the right eye showed no further myopic progression, while the left eye progressed by only 0.25 D. Visual acuity remained excellent at 6/6 in both eyes.
Conclusion
This case demonstrates that the combination of Defocus spectacle lenses and Myopine 0.01% was effective in slowing myopia progression and minimizing axial elongation, while maintaining excellent visual acuity over a long-term follow-up period.
成功病例报告：离焦镜片联合 0.01% 阿托品眼药水成功控制近视
一名15岁印度裔女生到 Family Eyecare Optometry Centre 接受近视控制治疗。2020年5月，其右眼近视为-5.50D，左眼为-4.50D。虽然期间配戴Executive Bifocal双光眼镜，但在随后18个月内近视仍快速加深至右眼-7.75D及左眼-6.75D。
由于近视进展明显，于2021年11月开始采用离焦近视控制镜片联合Myopine 0.01%阿托品眼药水进行治疗。
在2022年3月、2023年11月及2026年1月复查时，近视度数均保持相对稳定。2026年1月最终验光结果如下：
右眼：-7.75/-0.75 × 140（视力6/6）
左眼：-7.00/-0.50 × 10（视力6/6）
眼轴长度（AXL）变化亦相当轻微。右眼由26.14 mm增加至26.31 mm，而左眼则维持在约26.03 mm。
经过超过4年的联合治疗，右眼近视度数没有进一步增加，左眼仅增加0.25D，双眼最佳矫正视力均维持在6/6。
结论
本病例显示，近视控制镜片联合Myopine 0.01%眼药水能有效减缓近视加深及眼轴增长，并在长期追踪中维持良好的视力表现。
Your Vision Our Passion !
